Exagen 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Exagen reported 3rd quarter revenue of $18.4 million, up 7%, and said it was the best 3rd quarter in company history.
- Year-to-date revenue grew more than 11%, while adjusted EBITDA improved more than 30%; 3rd quarter adjusted EBITDA loss was $1.9 million, compared with a loss of $1.9 million last year.
- Year-to-date volume was up 8%; 3rd quarter ViCTD test volume grew 2%, and the number of ordering physicians increased 5%.
- Trailing 12-month ASP reached a record $451 per test, up $10 year over year and marking the 14th consecutive quarter of improvement.
- Pharma services revenue was over $900,000 in the 3rd quarter and $2.2 million year to date, up nearly 85% over last year; its contract backlog stood at roughly $5.5 million.
- Gross margin was just under 59%, up about 40 basis points, and total operating expenses were $15.2 million.
- Exagen ended the quarter with just over $28 million in cash and equivalents after adding about $6.5 million through its ATM program; after drawing $5 million from its Perceptive Debt Facility, pro forma cash at quarter-end was just over $33 million.
- Avise CTD revenue for the quarter was $16.4 million.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to the Exagen third quarter 2026 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Tina Jacobsen, head of investor relations. Please go ahead. Thanks, operator.
Good morning, and thank you for joining us to discuss Exagen's financial results for the quarter ended September 30, 2026. Today, I am joined by John Aballi, our President and Chief Executive Officer, and Jeff Black, our Chief Financial Officer. The recording of this call, the press release announcing our financial results, and a slide presentation can be accessed on our website at www.exagen.com. Today's call will include forward-looking statements. We encourage you to review the statements contained in today's press release and the risks and uncertainties described in our SEC filings, which identify certain factors that may cause the company's actual events, performance, and results to differ materially from those contained in the forward-looking statements made on today's call.
We also will discuss non-GAAP financial measures on this call. Descriptions of these non-GAAP financial measures and the reconciliations of GAAP to non-GAAP financial measures are included in today's press release. Now, I will turn the call over to John Aballi.
John? Good morning, everyone, and thank you for joining us.
The third quarter extended what is fast becoming a record year for Exagen, with execution toward our vision increasingly evident in the results. I will get right into the details. This morning, we reported third quarter revenue of $18.4 million, the best third quarter in company history. Year-to-date, revenue has grown more than 11%, which has contributed to an adjusted EBITDA improvement of over 30%. We grew both volume and price compared to last year. Trailing 12-month ASP reached a new record of $451, marking our 14th consecutive quarter of improvement. That speaks to the durability of our growth, and we are confidently reiterating full-year revenue guidance of $72 million-$75 million.
During the quarter, we utilized our ATM facility to strengthen the balance sheet and opportunistically brought in high-caliber investors as we continue to build and shape the company for the long term. We are really pleased to have their support. As always, our mission is at the heart of everything we do. Autoimmune disease is diagnosed too late and too inconsistently, and it is the patients that suffer. This is why Exagen exists, and we are singularly focused on building a unique platform to bring clarity to these complex diseases. I spent a good amount of time in the field with customers over the last few months, and the conversations I had reinforced the critical nature of our work and the strategic path we are taking.
I visited with customers here in Southern California, Louisiana, and New York to discuss our offerings, how we can better support their practices, and to preview new products that will address important diagnostic challenges. One of the groups I visited specifically validated the myositis offering we are readying for launch early next year, and we discussed the types of patients that would benefit as a result of this offering. Feedback like that is motivating, and with this new product, we are looking forward to serving even more autoimmune patients in need. With roughly 3%-4% share of an autoimmune testing market that we estimate at $2 billion plus, the opportunity ahead of Exagen is significant. We will capture more of that opportunity the same way we have reshaped this business, by focusing long-term and executing against three core objectives. The first, expanding adoption of our products.
The second being increasing reimbursement through disciplined value-based strategies and operations. Third, delivering a steady cadence of innovation to address the unmet needs of our clinicians. Let us jump into clinical adoption. You can see in the chart on this slide that year-to-date, volume is up 8%, and we are now approaching 1.3 million of AVISE CTD tests since launch. Third quarter of AVISE CTD volume was just above last year's test volume and in line with historical seasonality trends. In the fourth quarter, we expect continued normal seasonality with the holidays and annual societal meeting subsequently impacting the number of days physicians are in clinic. Our commercial investments are paying off well. We expanded to 45 territories over the past year, and while new reps typically take a year to get fully up to speed, productivity across the team continues to improve, and our ordering physician base continues to grow.
Our evidence base continues to expand as well. This is very much a strategic effort of ours, recognizing that reimbursement progress requires an ever-growing wave of high-quality content validating the utility of our products. On that note, today we are wrapping up at ACR Convergence in Orlando, where Exagen had a fantastic showing. Nine abstracts were featured at the conference, two of which were selected for podium presentations, one on disease associations for our proprietary T-cell markers and one analyzing phenotypic patterns across more than 375,000 of AVISE CTD results. The college reserves podium presentations for a small fraction of the abstracts it receives, and in 13 years of presenting at this meeting, this is only the second time in Exagen's history that it has earned two in a single year. Our science continues to push the boundaries of traditional autoimmune care, and our wave continues to build.
You may have noticed a new look for today's presentation. At ACR, we unveiled a refreshed Exagen brand with a modern, science-forward identity built around a new tagline, "Clarity in autoimmune decisions." It reflects who we are today and the leadership role we intend to play in autoimmune care. Over the coming months, we'll gradually be rolling out the new branding along with a website upgrade. Pharma Services delivered another strong quarter, with year-to-date revenue nearly doubling over last year. In support of partners across phase I through phase III trials, IVD development, and biobanking capabilities, we now offer 38 biomarkers, up from 32 last year. The programs we contribute to span lupus, RA, Sjögren's, myositis, among others, with RA demand growing fastest. It's further evidence that the data, biobank, and scientific capabilities we're building have value that extends well beyond the clinic. Turning to ASP. Trailing 12-month ASP expanded to $451 in the third quarter, up $10 year-over-year.
This remains the metric we use as operators to assess the business, because it smooths the variability associated with accrual accounting and the timing of collections. Our revenue cycle team delivered another solid quarter, and year-to-date recoveries on claims more than a year old are more than 2.5 times last year's level, as we continue to optimize processes with analytics and AI. We continue to work towards an ASP of roughly half our Medicare rate over time, and I'm confident there's more ground to gain in the coming quarters. This brings me to innovation, where we're positioning Exagen to serve our channel more comprehensively. Our myositis offering is on track for launch in early 2027.
We achieved meaningful milestones for the program this quarter by completing clinical and analytical validation, and we expect to submit our validation package to New York State Department of Health by the end of January. Myositis will be our first new standalone product since I joined, and we plan to launch it through our existing sales team, reaching the same rheumatologists who already rely on Exagen for the best connective tissue disease testing on the market. Work also continues on the customer-facing AI applications we mentioned last quarter, taking the AI successes we've had inside our own business and applying them to help clinicians run their practices more efficiently. During the quarter, we accelerated that effort by acquiring an AI-enabled workflow optimization platform for rheumatology practices, which we believe can streamline clinic operations and improve care for newly referred patients.
It's early, and we'll share more as development progresses, but my field visits during the quarter confirm the need for a solution like this that we're building. In an effort to provide greater clarity into some of the exciting science and products we're building, I'm pleased to announce that on December 15th at noon Eastern, we will host a webcast titled "Exagen Forward: Building the Autoimmune Platform." The event will offer a deeper dive into our myositis offering, as well as a couple other projects in our pipeline. More importantly, we'll show how Exagen's evolving from a single-product company into an autoimmune platform. Registration details are coming soon, and we really hope you'll be able to join us. To close, I want to step back and put Exagen's progress in perspective.
We are very focused on building long-term success, and results since the current management team arrived at the end of 2022 show that our strategy is working exceptionally well. Over this period, revenue has grown at a compounded rate of roughly 14%, while adjusted EBITDA loss has improved on average roughly 37% per year, now running roughly equal to our R&D investment. We achieved that while completely rebuilding many areas of the company, launching unique and novel biomarkers, establishing our Pharma Services business, and funding the pipeline that is taking us from a product to a platform. Today, the business is growing on both volume and price, our commercial engine is strengthening, and we are investing in our next leg of growth from a stronger balance sheet. This is the business we said we would build.
We will keep building it in the same way, quarter after quarter, focused on the long term and delivering on what we communicated. Before I hand the call over to Jeff, I want to thank our team. Progress like this is a tremendous amount of work, and the energy, effort, and high character our people bring every day in service of autoimmune patients and clinicians is what makes this progress possible. With that, I will turn it over to Jeff.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
